Inactive Instrument

LENZ Therapeutics, Inc. OTC Markets

GRPH

US52635N1037

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 07:00:00 2024-03-20 pm EDT			5-day change	1st Jan Change
22.26 ^USD	-2.75%		+3.58%	+21.37%

Apr. 15	Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target	MT
Apr. 15	William Blair Starts LENZ Therapeutics With Outperform Rating	MT

Graphite Bio, Inc.(NasdaqGM:GRPH) added to S&P TMI Index

September 20, 2021 at 12:00 am EDT

Latest news about LENZ Therapeutics, Inc.

Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target	Apr. 15	MT
William Blair Starts LENZ Therapeutics With Outperform Rating	Apr. 15	MT
LENZ Therapeutics Reports Positive Topline Data From Late-Stage Presbyopia Trials	Apr. 03	MT
LENZ Therapeutics, Inc. Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials	Apr. 03	CI
Lenz Therapeutics' eye disease drugs meet main goal of late-stage study	Apr. 03	RE
Piper Sandler Initiates LENZ Therapeutics at Overweight With $28 Price Target	Mar. 27	MT
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to NASDAQ Composite Index	Mar. 24	CI

LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.34%	103B
REGENERON PHARMACEUTICALS, INC.	+2.31%	96.56B
ARGENX SE	+4.22%	22.61B
BIONTECH SE	-16.72%	21.18B
GENMAB A/S	-4.50%	19.07B
WUXI APPTEC CO., LTD.	-41.75%	16.53B
BEIGENE, LTD.	-23.26%	14.46B
NEUROCRINE BIOSCIENCES, INC.	-0.02%	13.25B
SAREPTA THERAPEUTICS, INC.	+22.69%	11.1B

Bio Therapeutic Drugs

LENZ Therapeutics, Inc. OTC Markets

Equities

GRPH

US52635N1037

Biotechnology & Medical Research

Graphite Bio, Inc.(NasdaqGM:GRPH) added to S&P TMI Index

Latest news about LENZ Therapeutics, Inc.

Chart LENZ Therapeutics, Inc.

Company Profile

Sector Bio Therapeutic Drugs